18F-FDG PET and conventional imaging for assessment of Hodgkin's disease and non Hodgkin's lymphoma: An analysis of 193 patient studies

NuklearMedizin

Volumn 45, Issue 3, 2006, Pages 105-110

  Bucerius, Jan ^a   Herkel, C ^b   Joe, A Y ^a,b   Altehoefer, C ^b   Finke, J ^b   Moser, E ^b   Reinhordt, M J ^a,b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Computed tomography; Hodgkin's disease; Magnetic resonance imaging; Non Hodgkin's lymphoma; Positron emission tomography

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; SENSITIVITY AND SPECIFICITY;

EID: 33745901619     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1625326     Document Type: Article

References (37)

1. 18F-fluoro- 2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann Oncol 1998; 9: 1117-22.
2. Buchmann I, Reinhardt M, Elsner K et al. 2-(fluorine-18)fluoro-2-deoxy-D- glucose positron emission tomography in the detection and staging of malignant lymphomas. Cancer 2001; 91: 889-99.
3. Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol 1988; 6: 931-3.
4. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971; 31: 1860-1.
5. Clouse ME, Harrison DA, Grassi CJ et al. Lymphangiography, ultrasonography, and computed tomography in Hodgkin's disease and non-Hodgkin's lymphoma. J Comput Tomo 1985; 9: 1-8.
6. Coiffier B, Gisselbrecht C, Vose JM et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 1991; 9: 211-9.
7. Cremerius U, Fabry U, Kroll U et al. Clinical value of FDG PET for therapy monitoring of malignant lymphomas - results of a retrospective study of 72 patients. Nuklearmedizin 1999; 38: 24-30.
8. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. Ann Oncol 2001; 12: 29-37.
9. Gambhir SS, Czernin J, Schwimmer J et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:lS-93S.
10. Glenn LD, Kumar PP. The residual mediastinal mass following radiation therapy for Hodgkin's disease. Am J Clin Oncol 1991M 14: 16-24.
11. 18F-FDG in Hodgkin's disease for posttreatment evaluation. J Nucl Med 2003; 44: 1225-31.
12. Guppy AE, Tebbutt NC, Norman A et al. The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 123-5.
13. Harris NL, Jaffe ES, Diebold J et al. World Health Organization Classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee Meeting. Airlie House, Virginia, November 1997. J Clin Oncology 1999; 17: 3835-49.
14. Hermann S, Wormanns D, Pixberg M et al. Staging in childhood lymphoma. Differences between FDG-PET and CT. Nuklearmedizin 2005; 44: 1-7.
15. Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Sem Nucl Med 2005; 35: 165-76.
16. Höh CK, Glaspy J, Rosen P et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphomas. J Nucl Med 1997; 38: 343-8.
17. Israel O, Front D, Lam M et al. Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer 1988; 61: 2439-43.
18. Jerusalem G, Beguin Y, Fassotte MF et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123-30.
19. 18FDG-PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 13-20.
20. Jochelson M, Mauch P, Balikian J et al. The significance of the residual mediastinal mass in treated Hodgkin's disease. J Clin Oncol 1985; 3: 637-40.
21. Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears? Eur J Nucl Med 2000;27:1564-78.
22. Lister TA, Crowther D, Sutcliffe SB et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: the Cotswoldmeeting. J Clin Oncol 1989; 7: 1630-6.
23. Moog F, Bangerter M, Diederichs CG et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203: 795-800.
24. 18F-fluorodeoxyglucose- positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol 1998; 16: 603-9.
25. Moog F, Bangerter M, Diederichs CG et al. Extranodal malignant lymphoma: detection with FDG-PET versus CT. Radiology 2003; 206: 475-81.
26. Munker R, Stengel A, Stabler A et al. Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Verification by laparotomy in 100 cases. Cancer 1995; 76: 1460-6.
27. Newman JS, Francis IR, Kaminski MS et al. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994; 190: 111-6.
28. Radford JA, Cowan RA, Flanagan M et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988; 6: 940-6.
29. Rankin SC. Assessment of response to therapy using conventional imaging. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1): S56-64.
30. Reinhardt MJ, Ehritt-Braun C, Vogelsang D et al. Metastatic lymph nodes in patients with cervical cancer: detection with MR imaging and FDG PET. Radiology; 218: 776-82.
31. Schöder H, Larson SM, Yeung HWD. PET/CT in Oncology: Integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004; 45: 72S-81.
32. Stumpe KD, Urbinelli M, Steinert HC et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998; 25: 721-8.
33. Surbone A, Longo DL, DeVita VT et al. Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination therapy: significance and management. J Clin Oncol 1988; 6: 1832-7.
34. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl 1): S42-55.
35. 18F-fluorodeoxyglucose positron emission tomography in lymphoma. Leuk Lymphoma 2003; 44: 15-22.
36. Wiedmann E, Baican B, Hertel A et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. Leuk Lymphoma 1999; 34: 545-51.
37. Zinzani P, Magagnoli M, Chierichetti F et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999; 10: 1181-4.